Precision Health Clinical Trials
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
Conditions: Glioblastoma; GBM
Intervention: Biological: AZD1775
Sponsors: St. Joseph's Hospital and Medical Center, Phoenix; The Ben & Catherine Ivy Foundation; American Society of Clinical Oncology; Barbara Ann Karmanos Cancer Institute; Translational Genomics Research Institute, Phoenix, Arizona.
Recruiting - verified March 2016
Intervention: Biological: AZD1775
Sponsors: St. Joseph's Hospital and Medical Center, Phoenix; The Ben & Catherine Ivy Foundation; American Society of Clinical Oncology; Barbara Ann Karmanos Cancer Institute; Translational Genomics Research Institute, Phoenix, Arizona.
Recruiting - verified March 2016
For more information, visit the Study URL.
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
For more information, visit the Study URL.
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Conditions: Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Other: cytology specimen collection procedure; Drug: MEK 162 therapy or molecularly targeted therapy; Procedure: therapeutic procedure; Other: laboratory biomarker analysis; Other: quality-of-life assessment
Sponsors: Yale University; National Cancer Institute (NCI)
Recruiting - verified November 2016
Interventions: Other: cytology specimen collection procedure; Drug: MEK 162 therapy or molecularly targeted therapy; Procedure: therapeutic procedure; Other: laboratory biomarker analysis; Other: quality-of-life assessment
Sponsors: Yale University; National Cancer Institute (NCI)
Recruiting - verified November 2016
For more information, visit the Study URL.